Loading...
Uploaded by newsinfusion on Apr 12, 2011
NX-1207, a novel drug designed by Nymox Pharmaceutical to reduce prostate enlargement and improve urination, is now being evaluated in phase three clinical trials, the last step before filing for FDA approval. For more, visit www.newsinfusion.com
Science & Technology
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)